Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | CAR T across hematological malignancies: trials to watch

John Rossi • 12 Sep 2018
SOHO 2018
Acute Lymphoblastic Leukemia B-Cell Lymphoma Chronic Lymphocytic Leukemia Leukemia Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T KITE 585
ZUMA-2 ZUMA-3 ZUMA-4 ZUMA-5 ZUMA-7 ZUMA-8

Axicabtagene ciloleucel, an anti-CD19 CAR T-cell product, has shown impressive efficacy in diffuse large B-cell lymphoma already. In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, John Rossi, MS, from Kite Pharma Inc., Santa Monica, CA, highlights clinical trials in the ZUMA series which are targeting a variety of B-cell malignancies and leukemias with axicabtagene ciloleucel. He also discusses KITE 585, an anti-BCMA CAR T product which is being tested at Phase 1 (NCT03318861) in multiple myeloma.

More from John Rossi

3:32
ZUMA-1: updated data and future prospects
John Rossi • 12 Sep 2018
3:08
Identifying patient subgroups to improve outcome, resistance and toxicity in CAR T
John Rossi • 12 Sep 2018

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals